近5日资金流向一览见下表： 证券之星消息，截至2026年2月12日收盘，开立医疗(300633)报收于26.88元，上涨0.3%，换手率0.6%， 成交量2.6万手，成交额6960.7万元。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 2月12日的资金流向数据方面，主力资金净流入183.14万元，占总成交额2.63%，游资资金净流出571.2 万元，占总成交额8.21%，散户资金净流入388.07万元，占总成交额5.58%。 该股主要指标及行业内排名如下： 资金流向名词解释：指通过价格变化反推资 ...

近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 蓝帆医疗2025年三季报显示，前三季度公司主营收入41.82亿元，同比下降10.15%；归母净利润-2.86亿 元，同比下降30.09%；扣非净利润-3.64亿元，同比下降46.25%；其中2025年第三季度，公司单季度主 营收入14.01亿元，同比下降15.02%；单季度归母净利润-1.51亿元，同比下降153.64%；单季度扣非净利 润-1.55亿元，同比下降151.16%；负债率41.01%，投资收益1348.2万元，财务费用1.4亿元，毛利率 13.66%。蓝帆医疗（002382）主营业务：心脑血管业务、健康防护业务、应急救护业务、新营销业 务。 证券之星消息，截至2026年2月12日收盘，蓝帆医疗(002382)报收于5.81元，下跌1.86%，换手率 0.85%，成交量8.53万手，成交额4982.41万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量 ...

格隆汇2月12日丨欧普康视(300595.SZ)公布，近日收到国家药品监督管理局出具的《受理通知书》，公 司申请医疗器械产品"硬性接触镜冲洗液"注册申请已获国家药品监督管理局受理。硬性接触镜日常护理 和保养中，对镜片的冲洗是其中的一个护理环节，以提高镜片清洁度、戴镜安全性和舒适性。 ...

格隆汇2月12日丨欧普康视(300595.SZ)公布，近日收到国家药品监督管理局出具的《受理通知书》，公 司申请医疗器械产品"硬性接触镜冲洗液"注册申请已获国家药品监督管理局受理。硬性接触镜日常护理 和保养中，对镜片的冲洗是其中的一个护理环节，以提高镜片清洁度、戴镜安全性和舒适性。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in a Phase III trial for primary progressive multiple sclerosis (PPMS), marking a significant advancement in treatment options for this condition [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with Roche's Ocrevus projected to generate CHF 7 billion in sales by 2025, indicating substantial unmet needs in the PPMS segment [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% and medical services increasing by 1.3% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial included 985 PPMS patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11]. - The trial results suggest potential benefits for upper limb function, reinforcing the viability of BTK inhibitors in MS treatment [3][25]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth over the next few years [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x, indicating a premium valuation for the sector [35][36]. - Within the sector, chemical pharmaceuticals and biological products have higher valuations at 45.18x and 46.09x, respectively [35].

国外 道明证券将美联储下次降息时间点的预测从此前的3月推迟至6月，仍预计今年将累计降息75个基点，降 至终端利率3%。道明证券预计美联储将在6月、9月和12月各进行一次25个基点的降息。该机构首席美 国宏观策略师Oscar Munoz领衔的团队表示，预期中的政策宽松并非源于经济状况恶化，而是随着通胀 逐步回到目标水平，货币政策走向"正常化"的结果。就业前景改善应能让美联储把注意力转向通胀任 务。该机构同时预计，美债收益率今年将会继续下行，10年期收益率至年末将降至3.75%（此前预计为 3.5%）。 3. 野村：高市早苗政府有望加强财政纪律，日元走强 日元相对其他G10及亚洲货币走强。野村外汇研究分析师在报告中指出，日本首相高市早苗在财政政策 上可能变得更加"负责"，这将为外汇市场带来了一定缓解。分析师指出，有关如何为日本的消费税暂时 减免提供资金的讨论正在升温。分析师补充称，政府可能会利用"外汇基金特别账户"的盈余来支持此次 消费税减免。 4. Monex宏观研究负责人：美联储3月降息的可能性已消除 Monex的宏观研究负责人Nick Rees在报告中表示，对于美联储而言，1月美国就业数据表现强劲，"应当 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has experienced a decline, with significant net outflows from major funds, indicating potential concerns among institutional investors [1][2]. Financial Performance - As of February 12, 2026, United Imaging Healthcare's stock closed at 127.22 yuan, down 1.0% with a trading volume of 43,100 hands and a transaction value of 549 million yuan [1]. - In the recent three quarters, the company reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit of 1.12 billion yuan, up 66.91% [3]. - The third quarter of 2025 saw a single-quarter main revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit of 122 million yuan, up 143.8% [3]. Market Position - United Imaging Healthcare has a total market value of 104.849 billion yuan, ranking second in the medical device industry, with a net asset of 20.805 billion yuan, ranking third [3]. - The company's price-to-earnings ratio (P/E) is 70.2, which is lower than the industry average of 84.83, ranking 66th [3]. - The gross margin stands at 47.02%, slightly below the industry average of 51.01%, ranking 80th [3]. Fund Flow Analysis - On February 12, 2026, the net outflow of major funds was 52.849 million yuan, accounting for 9.62% of the total transaction value, while retail investors saw a net inflow of 37.8691 million yuan, representing 6.89% [1][2]. - Over the past five days, the trend shows consistent net outflows from major funds, indicating a potential bearish sentiment among institutional investors [2]. Analyst Ratings - In the last 90 days, 13 institutions have rated the stock, with 9 buy ratings and 4 hold ratings, and the average target price set at 174.86 yuan [4].

Core Viewpoint - The company has successfully integrated multiple cutting-edge intelligent technologies into its surgical robots, which are now in mass production [1] Group 1: Product Development - The company has obtained registration certificates for hip joint surgical robots, knee joint surgical robots, and unicompartmental surgical robots [1] - The products form a comprehensive digital orthopedic solution covering preoperative, intraoperative, and postoperative stages [1] Group 2: International Business Strategy - The company is actively responding to the national "Belt and Road" initiative and is steadily advancing its international business layout [1]

作为全球首个获准开展商业化应用的远程手术机器人系统，图迈远程手术机器人已在中国、印度、巴西 等近10个国家获得上市批准，其应用已覆盖全球近一半人口所在区域，并已率先进入常态化、规模化临 床应用阶段。截至目前，图迈已完成远程手术近800例，覆盖20多个国家，实施成功率继续保持100%。 在全球化布局持续加速的同时，图迈在单中心临床应用深度方面亦不断取得突破性进展。根据内部数据 统计，截至目前已完成图迈商业化装机的各国医疗机构中，单中心手术量超过百例的已有数十家，并广 泛覆盖泌尿外科、普通外科、胸外科、妇科、小儿外科、头颈外科等多个科室。 微创机器人-B(02252)发布公告，截至本公告日，集团核心产品图迈腔镜手术机器人全球商业化订单突 破200台，覆盖近50个国家和地区，已完成商业化装机近130台。图迈商业化订单和装机规模的再次里程 碑式跃升，标志着其临床价值在全球范围内获得持续、广泛的认可，是对图迈安全性、稳定性、可靠性 的系统性认证。来自不同国家、不同医疗体系、不同专科背景的外科医生，正在以真实而审慎的临床决 策，将图迈纳入日常手术实践与长期学科建设之中。 在已覆盖的近50个国家和地区中，订单数超5台的达1 ...

在全球化布局持续加速的同时，图迈在单中心临床应用深度方面亦不断取得突破性进展。根据内部数据 统计，截至目前已完成图迈商业化装机的各国医疗机构中，单中心手术量超过百例的已有数十家，并广 泛覆盖泌尿外科、普通外科、胸外科、妇科、小儿外科、头颈外科等多个科室。 智通财经APP讯，微创机器人-B(02252)发布公告，截至本公告日，集团核心产品图迈®腔镜手术机器人 全球商业化订单突破200台，覆盖近50个国家和地区，已完成商业化装机近130台。图迈商业化订单和装 机规模的再次里程碑式跃升，标志着其临床价值在全球范围内获得持续、广泛的认可，是对图迈安全 性、稳定性、可靠性的系统性认证。来自不同国家、不同医疗体系、不同专科背景的外科医生，正在以 真实而审慎的临床决策，将图迈纳入日常手术实践与长期学科建设之中。 在已覆盖的近50个国家和地区中，订单数超5台的达12个，新兴市场代表印度、巴西、阿根廷增长强 劲，其中印度累计订单已达14台，巴西超过10台;发达国家市场持续突破，西班牙、澳大利亚等国家成 为快速增长点。图迈商业化已在全球范围内形成多区域协同共振的新格局，贯穿发展中国家新兴市场以 及发达国家成熟医疗体系。 作为全球 ...